跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BIVALIRUDIN HMH bivalirudin (as trifluoroacetate) 250 mg powder for injection vial - TGA Drug Approval Details
Approvals
/
TGA
/
BIVALIRUDIN HMH bivalirudin (as trifluoroacetate) 250 mg powder for injection vial
Approved
STANDARD
BIVALIRUDIN HMH bivalirudin (as trifluoroacetate) 250 mg powder for injection vial
Southern XP IP Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
76e92ae7cf3df949
Company
Southern XP IP Pty Ltd
Type
Standard
Approval Details
Approval Id
76e92ae7cf3df949
Product Name
BIVALIRUDIN HMH bivalirudin (as trifluoroacetate) 250 mg powder for injection vial
Artg Id
388790
Artg Name
BIVALIRUDIN HMH bivalirudin (as trifluoroacetate) 250 mg powder for injection vial
Sponsor
Southern XP IP Pty Ltd
Company Detail Path
/organization/southern-xp-ip-pty-ltd
Artg Date
2023-06-08
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
76e92ae7cf3df949
Type
Standard
Back to TGA Approvals
